Danaher Corporation (DHR)
NYSE: DHR · Real-Time Price · USD
239.38
-2.15 (-0.89%)
Nov 14, 2024, 4:00 PM EST - Market closed
Danaher Employees
Danaher had 63,000 employees as of December 31, 2023. The number of employees decreased by 18,000 or -22.22% compared to the previous year.
Employees
63,000
Change (1Y)
-18,000
Growth (1Y)
-22.22%
Revenue / Employee
$376,857
Profits / Employee
$61,778
Market Cap
172.90B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 63,000 | -18,000 | -22.22% |
Dec 31, 2022 | 81,000 | 1,000 | 1.25% |
Dec 31, 2021 | 80,000 | 11,000 | 15.94% |
Dec 31, 2020 | 69,000 | 9,000 | 15.00% |
Dec 31, 2019 | 60,000 | -11,000 | -15.49% |
Dec 31, 2018 | 71,000 | 4,000 | 5.97% |
Dec 31, 2017 | 67,000 | 5,000 | 8.06% |
Dec 31, 2016 | 62,000 | -19,000 | -23.46% |
Dec 31, 2015 | 81,000 | 10,000 | 14.08% |
Dec 31, 2014 | 71,000 | 5,000 | 7.58% |
Dec 31, 2013 | 66,000 | 3,000 | 4.76% |
Dec 31, 2012 | 63,000 | 4,000 | 6.78% |
Dec 31, 2011 | 59,000 | 10,800 | 22.41% |
Dec 31, 2010 | 48,200 | 1,600 | 3.43% |
Dec 31, 2009 | 46,600 | -3,700 | -7.36% |
Dec 31, 2008 | 50,300 | 300 | 0.60% |
Dec 31, 2007 | 50,000 | 5,000 | 11.11% |
Dec 31, 2006 | 45,000 | 5,000 | 12.50% |
Dec 31, 2005 | 40,000 | 5,000 | 14.29% |
Dec 31, 2004 | 35,000 | 5,000 | 16.67% |
Dec 31, 2003 | 30,000 | 1,000 | 3.45% |
Dec 31, 2002 | 29,000 | 6,000 | 26.09% |
Dec 31, 2001 | 23,000 | -1,000 | -4.17% |
Dec 31, 2000 | 24,000 | 5,000 | 26.32% |
Dec 31, 1999 | 19,000 | 1,000 | 5.56% |
Dec 31, 1998 | 18,000 | 4,800 | 36.36% |
Dec 31, 1997 | 13,200 | 1,600 | 13.79% |
Dec 31, 1996 | 11,600 | 1,100 | 10.48% |
Dec 31, 1995 | 10,500 | 540 | 5.42% |
Dec 31, 1994 | 9,960 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Pfizer | 88,000 |
Novartis AG | 76,057 |
Boston Scientific | 48,000 |
Amgen | 26,700 |
Stryker | 26,700 |
DHR News
- 21 days ago - Understanding Danaher's Cautiousness - Seeking Alpha
- 23 days ago - Danaher's Q3 Earnings Boosted By Bioprocessing Order Growth, Analyst Maintain Stock Rating - Benzinga
- 23 days ago - Danaher Corporation (DHR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 24 days ago - Danaher beats quarterly profit estimates on strong demand for bioprocessing unit - Reuters
- 24 days ago - Danaher Reports Third Quarter 2024 Results - PRNewsWire
- 6 weeks ago - 3 Dividend Titans With Pricing Power Straight From The Hedge Fund Playbook - Seeking Alpha
- 7 weeks ago - Danaher Q3 Preview: Market Share Gains In Molecular Testing - Seeking Alpha
- 7 weeks ago - Automated and Closed Cell Therapy Market Research 2024-2029 Featuring Leading Players - Danaher, Thermo Fischer Scientific, Lonza, and Sartorius - GlobeNewsWire